For Immediate Release
Chicago, IL – March 28, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Amgen ( (AMGN - Free Report) , Sanofi ( (SNY - Free Report) , Regeneron ( (REGN - Free Report) , Alnylam ( (ALNY - Free Report) and Coach Inc. ( .
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: https://at.zacks.com/?id=5513
Here are highlights from Tuesday’s Analyst Blog:
Encouraging Data on Amgen Candidate
Amgen ( (AMGN - Free Report) recently presented positive data on its hypercholesterolemia candidate, AMG145. Results were presented at the American College of Cardiology Scientific Session from a phase Ib study that was conducted in high cholesterol patients taking statins.
Results in Detail
AMG 145, a fully human monoclonal antibody, is a PCSK9 inhibitor. The phase Ib study (n=51) was conducted to evaluate the safety, efficacy and tolerability of AMG145 compared to placebo. Results showed that patients on low to moderate doses of statin experienced a mean reduction in LDL-C (bad cholesterol) levels of up to 75% (at week 6) when administered AMG145 every two weeks.
Patients on low-to-moderate doses of statin experienced a mean reduction in LDL-C (bad cholesterol) levels of up to 66% (at week 8) when administered AMG145 every four weeks. Meanwhile, patients on high doses of statin experienced a mean reduction in LDL-C (bad cholesterol) levels of up to 63% (at week 6) when administered AMG145 every two weeks.
Amgen said that the magnitude and duration of effect depended on the dose, with PCSK9 being undetectable at higher doses.
Phase II Studies Ongoing
AMG145 is currently in a phase II program consisting of six studies which will involve about 1,900 patients. The program will not only evaluate AMG145 plus statins in patients with or at risk for cardiovascular disease, it will also be studied in patients who cannot tolerate statins. Besides this, AMG145 will be evaluated as a stand-alone treatment in patients with low cardiovascular risk, and in patients with heterozygous familial hypercholesterolemia. Amgen said that results from these studies should be out later this year.
Although statins (the current standard of treatment) are effective, many patients have problems achieving their cholesterol goals. Moreover, several patients are unable to tolerate statin therapy. In such a scenario, the successful development of PCSK9 inhibitors would be a major breakthrough in the area of cholesterol management. Besides Amgen, several other companies are working on developing PCSK9 inhibitors for cholesterol management.
Companies working on PCSK9 inhibitors include Sanofi ( (SNY - Free Report) /Regeneron ( (REGN - Free Report) and Alnylam ( (ALNY - Free Report) .
Outperform on Amgen
We currently have an Outperform recommendation on Amgen, which carries a Zacks #2 Rank (short-term “Buy” rating). We are bullish on Prolia/Xgeva and we expect Amgen to utilize its cash towards share buybacks and acquisitions or deals that will help boost its pipeline and drive long-term growth.
Coach’s Balancing Act
Being a leading American marketer of fine accessories and gifts, Coach Inc. ( boasts of a proven strategy of investing in stores to enhance sales productivity through product innovation, compelling pricing strategy, new merchandise assortments and a cost-effective global sourcing model, which should drive comparable-store sales and operating margins in the long term.
Management remains confident of sustaining double-digit growth in both top and bottom lines in fiscal 2012. The company’s long-term growth drivers include expansion of its global distribution model and entry into under-penetrated markets. The company lays more emphasis on globalization and accelerated international distribution growth.
After North America and Asia, Coach also extended its global footprint in Europe. It is also investing in rapidly growing emerging markets, such as China, Brazil, Vietnam and Kuwait to increase its brand awareness.
Management now expects to achieve at least $300 million in sales in fiscal 2012 in China, backed by the sustained growth momentum it is currently witnessing. As a part of its strategy to directly control certain Asian markets, Coach is now directly operating its retail business in Singapore and Taiwan. The company is also under discussion to acquire its Malaysian retail business in July.
Coach maintains a healthy balance sheet with significant cash balance and negligible debt load. The company also has been proactively managing its cash flows by making prudent capital investments and enhancing shareholder returns. The company’s strong liquidity positions it well to drive future growth.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: https://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: https://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at https://at.zacks.com/?id=5518.
Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339